Cargando…
Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007781/ http://dx.doi.org/10.1186/1479-5876-8-S1-P37 |